ArticleJournal of hematology2025
Acute Undifferentiated Leukemia Presented With Mediastinal Sarcoma.
Article in Journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute undifferentiated leukemia (AUL) is a rare, aggressive type of acute leukemia associated with poor prognosis, in which the blasts lack lineage commitment to either the myeloid or lymphoid lineages. It is classified according to the World Health Organization (WHO) classification under the category of acute leukemias of ambiguous lineage (ALAL). Here we present a case of a 20-year-old man, who was referred to Military Cancer Center in February 2025, as a case of mediastinal myeloid sarcoma, which was diagnosed by biopsy of the mass. Bone marrow examination was performed in our center and showed infiltration by blasts, flow cytometry of bone marrow aspirate specimen revealed that blasts do not express lineage-specific markers with expression of primitive markers, so the diagnosis of AUL was established. For precise diagnosis of AUL, a comprehensive and broad panel of immunomarkers should be run to rule out any lineage commitment for the clone. Review of literature revealed only one previously published similar case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.